GeoVax Labs, Inc. (Nasdaq: GOVX) on Monday underscored the growing need for scalable domestic vaccine manufacturing capabilities as global infectious disease threats intensify. The clinical-stage biotechnology company pointed to recent public health emergencies, including the World Health Organization's declaration of a Public Health Emergency of International Concern for an Ebola outbreak involving the Bundibugyo strain, the continued international spread of Clade I mpox, and hantavirus-related concerns, as evidence that the world requires a more robust and flexible preparedness infrastructure.
“These developments reinforce the importance of scalable and flexible vaccine preparedness infrastructure,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “GeoVax’s primary strategic focus remains the advancement of GEO-MVA, our Modified Vaccinia Ankara (MVA) mpox and smallpox vaccine candidate, which we believe is well aligned with growing global emphasis on diversified vaccine supply, domestic manufacturing capability, and long-term biodefense preparedness.”
GeoVax is advancing GEO-MVA to support global orthopoxvirus preparedness and address the need for expanded vaccine supply. The company recently announced positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway toward potential regulatory approval. The pivotal Phase 3 trial is scheduled to initiate in the fourth quarter of 2026, with data results anticipated by mid-2027.
The company believes recent infectious disease developments reinforce the strategic importance of diversified vaccine supply infrastructure, scalable domestic manufacturing capabilities, rapid-response vaccine platform technologies, and long-term investment in biodefense preparedness. GeoVax also noted that the broader applicability of the MVA platform has been demonstrated in prior preclinical Ebola studies, where its MVA-based Ebola-Zaire vaccine candidate showed complete protection in non-human primate lethal-challenge studies.
“Recent events continue to demonstrate that preparedness infrastructure cannot remain reactive or narrowly focused on individual outbreak cycles,” continued Mr. Dodd. “We believe the advancement of scalable domestic MVA-based manufacturing capability represents an important strategic objective for strengthening future biodefense readiness.”
GEO-MVA is a next-generation MVA-based vaccine candidate for the prevention of mpox and smallpox infection. It is designed to support expanded global vaccine supply and diversified manufacturing capabilities. For more information, visit GeoVax's website.
